Clinical
Trials
Taletrectinib
We are conducting Phase 2 trials of taletrectinib in ROS1 positive NSCLC patients both as first-line and second-line treatments in China. More information about the ongoing Phase 2 trials may be found at clinicaltrials.gov with NCT04395677.
Two Phase 1 trials, one in the US and the other in Japan, have been completed and are currently in extension phase with 7 patients remaining under treatment.
More information about the Phase 1 program may be found at clinicaltrials.gov with NCT02279433, and NCT0267591.
These trials have been closed to new patient enrollment.
“Taletrectinib (AB106/DS6051b) demonstrated meaningful clinical activity in advanced ROS1+NSCLC patients who are ROS1 TKI-naive or crizotinib-refractory and a manageable safety profile.”
– Sai-Hong Ignatius Ou, M.D., Ph.D.
Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, CA, USA
Contact Us
For questions about ongoing clinical trials, please contact trials@anhearttherapeutics.com
